Study suggests tumour microenvironments could predict cancer progression
NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases
Read More
Tag: Bristol Myers Squibb
Cancer treatment could identify patients most likely to respond to cancer drugs
Tumours with high mtDNA mutations more likely to respond to Opdivo
Read More
- KCL researchers identify key features of autoimmune diseases present in the gut
- Vicore and Endeavor’s therapies show promise in treating IPF
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
